| [1] |
一戸，彰. 慢性肝疾患に対する強力ネオミノフォ-ゲンC (SNMC)の治療知見[J]. 臨牀と研究,53(8):2532-2539, 1976-2008.
|
| [2] |
Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization[J]. Ann Intern Med,2003,139(6):493-498.
|
| [3] |
Guyatt GH, Oxman AD, Vist GE, et al. Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ,2008,336(7650):924-926.
|
| [4] |
Zhu S, Li W, Ward MF, et al. High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation[J]. Inflamm Allergy Drug Targets,2010,9(1):60-72.
|
| [5] |
Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection[J]. Annu Rev Immunol,2011,29:139-162.
URL
|
| [6] |
Gwak GY, Moon TG, Lee DH, et al. Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway[J]. World J Gastroenterol,2012,18(7):679-684.
|
| [7] |
Smolarczyk R, Cichon T, Matuszczak S, et al. The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy[J]. Arch Immunol Ther Exp (Warsz),2012,60(5):391-399.
|
| [8] |
Kuroda N, Inoue K, Ikeda T, et al. Apoptotic response through a high mobility box 1 protein-dependent mechanism in LPS/GalN-induced mouse liver failure and glycyrrhizin-mediated inhibition[J]. PLoS One,2014,9(4):e92884.
|
| [9] |
Vitali R, Palone F, Cucchiara S, et al. Dipotassium glycyrrhizate inhibits HMGB1-dependent inflammation and ameliorates colitis in mice[J]. PLoS One,2013,8(6):e66527.
|
| [10] |
Gong G, Yuan LB, Hu L, et al. Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1[J]. Acta Pharmacol Sin,2012,33(1):11-18.
URL
|
| [11] |
Zhai CL, Zhang MQ, Zhang Y, et al. Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway[J]. Acta Pharmacol Sin,2012,33(12):1477-1487.
URL
|
| [12] |
Xiang K, Cheng L, Luo Z, et al. Glycyrrhizin suppresses the expressions of HMGB1 and relieves the severity of traumatic pancreatitis in rats[J]. PLoS One,2014,9(12):e115982.
|
| [13] |
Yang PS, Kim DH, Lee YJ, et al. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats[J]. Respir Res,2014,15:148.
|
| [14] |
Gong G, Xiang L, Yuan L, et al. Protective Effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats[J]. PLoS One,2014,9(3): e89450.
|
| [15] |
Mollica L, De Marchis F, Spitaleri A, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities[J]. Chem Biol,2007,14(4):431-441.
|
| [16] |
Cavone L, Cuppari C, Manti S, et al. Increase in the level of proinflammatory cytokine HMGB1 in nasal fluids of patients with rhinitis and its sequestration by glycyrrhizin induces eosinophil cell death[J]. Clin Exp Otorhinolaryngol,2015,8(2):123-128.
|
| [17] |
Wang CY, Kao TC, Lo WH, et al. Glycyrrhizic acid and 18β-glycyrrhetinic acid modulate lipopolysaccharide-induced inflammatory response by suppression of NF-κB through PI3K p110δ and p110γ inhibitions[J]. J Agric Food Chem,2011,59(14):7726-7733.
|
| [18] |
Mahmoud AM, Al Dera HS. 18β-glycyrrhetinic acid exerts protective effects against cyclophosphamide-induced hepatotoxicity: potential role of PPARγ and Nrf2 upregulation[J]. Genes Nutr,2015,10(6):41.
|
| [19] |
中华医学会感染病学分会，肝脏炎症及其防治专家共识专家委员会. 肝脏炎症及其防治专家共识[J]. 中华肝脏病杂志,2014,22(2):94-103.
|
| [20] |
晏泽辉，王宇明，汤勃, 等. 异甘草酸镁联合核苷类似物治疗慢性乙型肝炎的荟萃分析[J]. 中华肝脏病杂志,2014,22(2):108-112.
|
| [21] |
陈建蓉，王霁，秦天强, 等. 复方甘草酸苷治疗慢性乙型肝炎的效果及安全性的Meta分析[J]. 南方医科大学学报,2014,34(8):1224-1229.
|
| [22] |
张耀武. 恩替卡韦联合复方甘草酸苷治疗代偿期活动性乙型肝炎肝硬化患者的临床研究[J/CD]. 中国肝脏病杂志:电子版,2013,5(4):37-41.
|
| [23] |
Orlent H, Hansen BE, Willems M, et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase Ⅱ trial[J]. J Hepatol,2006,45(4):539-546.
|
| [24] |
Manns MP, Wedemeyer H, Singer A, et al. Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks[J]. J Viral Hepat,2012,19(8):537-546.
|
| [25] |
Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan[J]. Hepatol Res,2010,40(1):1-7.
|
| [26] |
Suzuki F. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2014 in Japan[J]. Nihon Rinsho,2015,73(2):215-220.
|
| [27] |
Ikeda K, Kawamura Y, Kobayashi M, et al. Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: a Markov model[J]. Oncology,2014,86(5-6):295-302.
URL
|
| [28] |
Tandon A, Tandon BN, Bhujwala RA. Clinical spectrum of acute sporadic hepatitis E and possible benefit of glycyrrhizin therapy[J]. Hepatol Res,2002,23(1):55-61.
|
| [29] |
Zhang L, Wang B. Randomized clinical trial with two doses (100 and 40 ml) of stronger neo-minophagen C in Chinese patients with chronic hepatitis B[J]. Hepatol Res,2002,24(3):220.
|
| [30] |
茹仁萍，吴锡铭. 18α-甘草酸及其脂质配位体的生物利用度与抗肝损害作用的比较[J]. 浙江医学,2001,23(8):466-468.
|
| [31] |
Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States[J]. Liver Transpl,2004,10(8):1018-1023.
|
| [32] |
Björnsson E, Jerlstad P, Bergqvist A, et al. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden[J]. Scand J Gastroenterol,2005,40(9):1095-1101.
|
| [33] |
张智峰，赵刚. 我国药物性肝损伤病因演变的Meta分析[J]. 医学与哲学,2013,34(10):9-13.
|
| [34] |
中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 中华肝脏病杂志,2015,23(11):810-820.
|
| [35] |
Yu J, Jiang YS, Jiang Y, et al. Targeted metabolomic study indicating glycyrrhizin's protection against acetaminophen-induced liver damage through reversing fatty acid metabolism[J]. Phytother Res,2014,28(6):933-936.
URL
|
| [36] |
Liang B, Guo XL, Jin J, et al. Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury[J]. World J Gastroenterol,2015,21(17):5271-5280.
|
| [37] |
Guo XL, Liang B, Wang XW, et al. Glycyrrhizic acid attenuates CCl4-induced hepatocyte apoptosis in rats via a p53-mediated pathway[J]. World J Gastroenterol,2013,19(24):3781-3791.
|
| [38] |
陈永芳，程俊伟，陈裕, 等. 异甘草酸镁注射液治疗抗结核药物所致急性肝损伤的疗效分析[J]. 北京医学,2014,36(3):223-225.
|
| [39] |
张子胜. 复方甘草酸苷预防结核药物性肝炎序贯治疗的临床研究[J]. 中外医疗,2014,34(34):11-12.
|
| [40] |
汤丽娜，林峰，沈赞, 等. 异甘草酸镁治疗抗肿瘤药物引起的急性药物性肝损伤的Ⅲ期临床试验[J]. 肿瘤,2012,32(9):738-743.
|
| [41] |
耿立霞，马宏杰，王永福, 等. 美能治疗化疗药物所致的肝损害疗效观察[J]. 中国误诊学杂志,2010,10(9):2084-2085.
|
| [42] |
李全志，段京莉. 甘草酸二铵治疗药物性肝损害的系统评价[J]. 中国药房,2010,21(12):1100-1105.
|
| [43] |
闫玉兰，莫永森，张冬梅. 异甘草酸镁对化疗药物致初治胃肠道肿瘤患者肝损害的预防作用[J]. 中华肝脏病杂志,2015,23(3):204-208.
|
| [44] |
中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病指南[J/CD]. 中国肝脏病杂志:电子版,2010,2(4):49-53.
|
| [45] |
李龙辉，李龙江，汤为学, 等. 甘利欣作用前后体外酒精性脂肪肝细胞模型甘油三酯水平变化及其可能作用机制[J]. 重庆医科大学学报,2010,35(2):179-182.
|
| [46] |
戴文聪. 急性酒精性脂肪肝斑马鱼模型的建立及异甘草酸镁保肝作用机制研究[D]. 南方医科大学,2013.
|
| [47] |
谢议凤，刘建国，刘庆, 等. 异甘草酸镁对小鼠急性酒精性肝损伤的保护作用[J]. 实用医学杂志,2010,26(3):381-383.
|
| [48] |
毛征批，金伟明，朱伟君, 等. 异甘草酸镁注射液对酒精性肝硬化疗效及氧化指标的影响[J]. 中国医师杂志,2014,16(2):263-265.
|
| [49] |
娄海山. 复方甘草酸苷治疗酒精性脂肪肝临床研究[J]. 亚太传统医药,2014,10(5):117-119.
|
| [50] |
孟巍，余良主，王利. 复方甘草酸苷改善酒精性肝病患者肝功能的Meta分析[J]. 中国药房,2013,24(12):1116-1118.
|
| [51] |
中华医学会肝病学分会脂肪肝和酒精性肝病学组. 中国非酒精性脂肪性肝病诊疗指南(2010年修订版)[J/CD]. 中国肝脏病杂志:电子版,2010,2(4):43-48.
|
| [52] |
Wu X, Zhang L, Gurley E, et al. Prevention of free fatty acid-induced hepatic lipotoxicity by 18β-glycyrrhetinic acid through lysosomal and mitochondrial pathways[J]. Hepatology,2008,47(6):1905-1915.
|
| [53] |
Maurya SK, Srivastava AK. Glycyrrhizic acid attenuates the expression of HMG-CoA reductase mRNA in high fructose diet induced dyslipidemic hamsters. Prague Medical Report,2011,112(1):29-37.
|
| [54] |
Honda H, Nagai Y, Matsunaga T, et al. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation[J]. J Leukoc Biol,2014,96(6):1087-100.
|
| [55] |
Cheng Y, Zhang J, Shang J, et al. Prevention of free fatty acid-induced hepatic lipotoxicity in HepG2 cells by magnesium isoglycyrrhizinate in vitro[J]. Pharmacology,2009,84(3):183-190.
|
| [56] |
田媛，唐晓辉，李鸿燕, 等. 异甘草酸镁联合降脂治疗中,重度NASH的疗效及机制分析[J]. 中国生化药物杂志,2014,34(2):122-124.
|
| [57] |
孙晓红，张良登，魏纬, 等. 甘草酸苷治疗非酒精性脂肪性肝炎的系统评价与Meta分析[J]. 世界中西医结合杂志,2015,10(2):265-271.
|
| [58] |
姚岚. 甘草酸类制剂治疗自身免疫性肝炎的研究进展[J]. 医学综述,2014,20(13):2336-2338.
|
| [59] |
Czaja AJ. Diagnosis and management of autoimmune hepatitis[J]. Clin Liver Dis,2015,19(1):57-79.
|
| [60] |
Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis[J]. Hepatology,2010,51(6):2193-2213.
|
| [61] |
Muriel P, Rivera-Espinoza Y. Beneficial drugs for liver diseases[J]. J Appl Toxicol,2008,28(2):93-103.
|
| [62] |
Yasui S, Fujiwara K, Tawada A, et al. Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis[J]. Dig Dis Sci,2011,56(12):3638-3647.
|
| [63] |
李蕴铷，王文冰，张黎颖, 等. 甘草酸类药物治疗自身免疫性肝炎疗效分析[J]. 临床肝胆病杂志,2007,23(2):117-118.
|
| [64] |
Qu Y, Zong L, Xu M, et al. Effects of 18alpha-glycyrrhizin on TGF-beta 1/Smad signaling pathway in rats with carbon tetrachloride-induced liver fibrosis[J]. Int J Clin Exp Pathol,2015,8(2):1292-1301.
|
| [65] |
Tu CT, Li J, Wang FP, et al. Glycyrrhizin regulates CD4+T cell response during liver fibrogenesis via JNK, ERK and PI3K/AKT pathway[J]. Int Immunopharmacol,2012,14(4): 410-421.
URL
|
| [66] |
Qu Y, Chen WH, Zong L, et al. 18 alpha-Glycyrrhizin induces apoptosis and suppresses activation of rat hepatic stellate cells[J]. Med Sci Monit,2012,18(1):BR24-32.
|
| [67] |
Zhao X, Deng B, Xu XY, et al. Glycyrrhizinate reduces portal hypertension in isolated perfused rat livers with chronic hepatitis[J]. World J Gastroenterol,2013,19(36):6069-6076.
|
| [68] |
Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma[J]. Oncology,2002,62(Suppl 1):94-100.
|
| [69] |
皇甫竞坤，闫杰，赵红, 等. 异甘草酸镁对乙型肝炎肝硬化合并腹水患者水钠潴留及相关安全性的影响[J/CD]. 中华临床医师杂志:电子版,2013,7(10):4200-4204.
|
| [70] |
Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients[J]. Cancer,1997,79(8):1494-1500.
|
| [71] |
Ikeda K, Arase Y, Kobayashi M, et al. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients[J]. Dig Dis Sci,2006,51(3):603-609.
|
| [72] |
Rino Y, Tarao K, Morinaga S, et al. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis[J]. Anticancer Res,2006,26(3B):2221-2226.
|
| [73] |
中华医学会感染病学分会肝衰竭与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版) [J]. 中华临床感染病杂志,2013,5(6):321-327.
|
| [74] |
杨宝山，马英骥，陈立艳, 等. 复方甘草酸苷对小鼠暴发性肝功能衰竭保护作用及机制研究[J]. 中华传染病杂志,2005,23(1):19-23.
|
| [75] |
刘潇聪，陈耀凯，李晖, 等. 复方甘草酸苷对重型肝炎的治疗作用及机制研究[J]. 第三军医大学学报,2009,31(18):1806-1808.
|
| [76] |
于仲青，杨宝山，王岩, 等. 复方甘草酸苷对暴发性肝衰竭患者的保护作用[J]. 世界华人消化杂志,2006,14(13):1318-1322.
|
| [77] |
Acharya SK, Dasarathy S, Tandon A, et al. A preliminary open trial on interferon stimulator (SNMC) derived from Glycyrrhiza glabra in the treatment of subacute hepatic failure[J]. Indian J Med Res,1993,98(1):69-74.
|
| [78] |
毛海鹰，康涛，姚玲, 等. 甘草酸类制剂治疗慢性重型乙型肝炎疗效的Meta分析[J]. 临床肝胆病杂志,2015,31(1):63-67.
|
| [79] |
甘泉，陈超，熊靓. 腹腔镜与开腹胆囊切除术对机体炎性反应的影响[J]. 中国医药指南,2013,11(2):82-83.
|
| [80] |
李书印. 复方甘草酸苷在原发性肝癌术中护肝疗效观察[J]. 中国医学创,2010,7(25):105-106.
|
| [81] |
张宪祥，张炳远，吴力群. 异甘草酸镁对肝切除术后的保肝作用[J]. 世界华人消化杂志,2010,18(2):189-194.
|
| [82] |
陈榕，韦伟，朱立元. 复方甘草酸苷对胆道结石术后退黄的临床效果观察[J]. 中国药房,2004,15(10):620-621.
|
| [83] |
白金霞，李怡莹. 甘草酸二铵致不良反应259例分析[J]. 现代医药卫生,2011,27(8):1251-1252.
|
| [84] |
王红霞，张共青. 复方甘草酸苷治疗新生儿高胆红素血症临床分析[J]. 包头医学,2012,36(2):83-84.
|
| [85] |
Hiromitsu K, Hiroyuki M, Kunio O, et al. Post-marketing study of stronger neo-minophagen C for elderly patients with chronic hepatitis C[J]. Geriat Med,2015,53(5):505-520.
|
| [86] |
Xu R, Liu X, Yang J. A semi-physiologically based pharmacokinetic pharmacodynamic model for glycyrrhizin-induced pseudoaldosteronism and prediction of the dose limit causing hypokalemia in a virtual elderly population[J]. PLoS One,2014,9(12):e114049.
|
| [87] |
Matsumoto Y, Matsuura T, Aoyagi H, et al. Antiviral activity of glycyrrhizin against hepatitis C virus in vitro[J]. PLoS One,2013,8(7):e68992.
|
| [88] |
高学松，高丽丽，芦红萍, 等. 复方甘草酸苷改善慢性乙型肝炎肝脏炎症的机制研究[J/CD]. 中华实验和临床感染病杂志:电子版,2015,9(4):52-55.
|
| [89] |
Wakamatsu T, Nakahashi Y, Hachimine D, et al. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins[J]. Int J Oncol,2007,31(6):1465-1472.
|